These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Schirner M, Hoffmann J, Menrad A, Schneider MR. Clin Cancer Res; 1998 May; 4(5):1331-6. PubMed ID: 9607594 [Abstract] [Full Text] [Related]
31. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D'Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O'Connell J, Allen R, Perry M, Jolliffe L, Middleton SA. Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256 [Abstract] [Full Text] [Related]
32. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. He GA, Luo JX, Zhang TY, Hu ZS, Wang FY. Biochem Biophys Res Commun; 2004 May 28; 318(2):354-60. PubMed ID: 15120609 [Abstract] [Full Text] [Related]
33. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, Karumanchi SA, Russell SJ, Sukhatme VP. J Natl Cancer Inst; 2006 Jun 07; 98(11):756-64. PubMed ID: 16757700 [Abstract] [Full Text] [Related]
34. Mouse endostatin inhibits the formation of lung and liver metastases. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK. Cancer Res; 1999 Dec 15; 59(24):6251-6. PubMed ID: 10626820 [Abstract] [Full Text] [Related]
36. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. Cancer Res; 2008 Jan 15; 68(2):521-9. PubMed ID: 18199548 [Abstract] [Full Text] [Related]
37. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri P, Ribatti D, Ponzoni M. Clin Cancer Res; 2007 Jul 01; 13(13):3977-88. PubMed ID: 17606732 [Abstract] [Full Text] [Related]
38. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M. Clin Cancer Res; 2005 Jul 01; 11(13):4934-40. PubMed ID: 16000592 [Abstract] [Full Text] [Related]
39. Embryonal mass and hormone-associated effects of pregnancy inducing a differential growth of four murine tumors. Bustuoabad OD, di Gianni PD, Franco M, Kordon EC, Vanzulli SI, Meiss RP, Grion LC, Díaz GS, Nosetto SH, Hockl P, Lombardi MG, Pasqualini CD, Ruggiero RA. Oncol Res; 2002 Jul 01; 13(3):147-60. PubMed ID: 12549624 [Abstract] [Full Text] [Related]
40. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D. Anticancer Res; 1998 Jul 01; 18(4A):2567-73. PubMed ID: 9703911 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]